Skip to main contentSkip to footer
A finger pointing at a scan
Brighton & Sussex Medical School

Staff Profiles

BSMS > About BSMS > Contact us > Staff > Professor Sube Banerjee

Professor Sube Banerjee

Prof Sube Banerjee

Professor Sube Banerjee (MBE, MB BS, MSc, MBA, MD, FRCPsych)

Honorary Visiting Professor
Location: Trafford Centre for Medical Research, Room 102, BSMS, University of Sussex, BN1 9RY

DA: Linda Bennett 
T: +44(0)1273 678472

Areas of expertise: Older people’s mental health; dementia; applied health research; quality of life research; outcomes; health policy; randomised controlled trials; epidemiology

Research areas: Dementia; applied health research; RCTs; service evaluation


Sube Banerjee is Professor of Dementia and Associate Dean at Brighton and Sussex Medical School, directing its Centre for Dementia Studies. Clinically he works as an old age psychiatrist. He was trained at St Thomas’, Guy’s and the Maudsley Hospitals. Before joining BSMS in 2012 he was the Professor of Mental Health and Ageing at the Institute of Psychiatry, King’s College London. He served as the UK Department of Health’s senior professional advisor on dementia leading the development of its National Dementia Strategy.

Sube is active in health system development and works with industry and governments on health systems, policy and strategies to improve health for older adults with complex needs and those with dementia. An active researcher, he focusses on quality of life in dementia, evaluation of new treatments and services, and the interface between policy, research and practice. He has been awarded national and international awards for work in policy and research in dementia.  


Sube’s research focuses on quality of life and quality of care in dementia. This involves first identifying/understanding the problems faced by those with dementia and their carers; second formulating effective, generalisable ways of addressing the problems identified; third evaluating the impact of these interventions; and finally disseminating the data and lessons derived, enabling policy change so they can be hardwired into clinical provision.

Quality of life in dementia

The experience of people with dementia and their carers is more than the sum of cognitive and behavioural measures. New treatments for dementia demand sound methodologies with which to measure overall response to treatments. Sube has been the PI on programmes of work to develop DEMQOL, a disease-specific quality of life measure for dementia. Research includes:

  • Development of a utility and monetary weighted instrument DEMQOL-U
  • Cross national studies of the natural history of quality of life in dementia
  • Further studies of the responsiveness of DEMQOL
  • Investigation of adaptation and response shift in dementia.
  • Studies of the impact of clinical service provision on quality of life in dementia
  • Development of C-DEMQOL an instrument to measure the quality of life of carers of people with dementia

Find out more about DEMQOL >


Quality of care in dementia

Work on how we provide services for older people with mental disorder and how can we improve them includes:

  • MODEM with LSE generating comprehensive clinico-economic model for dementia including life quality outcomes.
  • HTA-SADD Trial of antidepressants for depression in dementia (CI) – clinical and cost effectiveness data published.  
  • HTA-SMBAD Trial of mirtazapine and carbamazepine for agitation and aggression in dementia (CI)
  • Investigation of memory services and the process of diagnosis.
  • Development and evaluation of integrative strategies to address the “empty centre” of dementia care after diagnosis but before transition into institutional care
  • Quality of death, end of life care and advanced directives in dementia.
  • Memory services for people with HIV


Course principal – MSc in Dementia Studies
Director – Time for Dementia Programme
SSC – Quality of life and quality of care in dementia
Clinical lead – HEKSS Dementia Skills Development Programme

Selected publications

Banerjee S. Multimorbidity—older adults need health care that can count past one. The Lancet. 2015;385(9968):587-589.

Arokiasamy P, Uttamacharya U, Jain K, Biritwum R, Yawson A, Wu F et al. The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal?. BMC Medicine. 2015;13(1).

Burns A, Younger J, Morris J, Baldwin R, Tarrier N, Pendleton N et al. Outcomes Following Hip Fracture Surgery: A 2-Year Prospective Study. The American Journal of Geriatric Psychiatry. 2014;22(8):838-844.

Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial – a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess. 2013;17(07).

Mulhern B, Rowen D, Brazier J, Smith S, Romeo R, Tait R et al. Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation. Health Technol Assess. 2013;17(05).

Poppe M, Burleigh S, Banerjee S. Qualitative Evaluation of Advanced Care Planning in Early Dementia (ACP-ED). PLoS ONE. 2013;8(4):e60412.

Barnes T, Banerjee S, Collins N, Treloar A, McIntyre S, Paton C. Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. The British Journal of Psychiatry. 2012;201(3):221-226.

Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R et al. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. The British Journal of Psychiatry. 2012;202(2):121-128.

Click here to elements profile >